European heart journal
-
European heart journal · Dec 2013
Randomized Controlled Trial Multicenter Study Comparative StudyLosartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.
Patients with Marfan syndrome have an increased risk of life-threatening aortic complications, mostly preceded by aortic dilatation. Treatment with losartan, an angiotensin-II receptor-1 blocker, may reduce aortic dilatation rate in Marfan patients. ⋯ In adult Marfan patients, losartan treatment reduces aortic root dilatation rate. After aortic root replacement, losartan treatment reduces dilatation rate of the aortic arch.